Robert J. Lonigro

Active 2007–2021

43
Papers
24,672
Citations
42
h-index
43
i10-index

Citations

Citations per year for Robert J. Lonigro1985: 1 citations1993: 1 citations2003: 1 citations2004: 1 citations2005: 1 citations2006: 3 citations2007: 1 citations2008: 13 citations2009: 97 citations2010: 169 citations2011: 240 citations2012: 267 citations2013: 390 citations2014: 358 citations2015: 354 citations2016: 436 citations2017: 419 citations2018: 454 citations2019: 1,205 citations2020: 1,231 citations2021: 1,180 citations2022: 835 citations2023: 539 citations2024: 804 citations2025: 318 citations2026: 6 citations1986–1992: no citations, so these years are not shown1994–2002: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,910 citing papers, 31.8% of this breakdownChina: 1,443 citing papers, 11.7% of this breakdownUnited Kingdom: 841 citing papers, 6.8% of this breakdownCanada: 598 citing papers, 4.9% of this breakdownItaly: 570 citing papers, 4.6% of this breakdownGermany: 475 citing papers, 3.9% of this breakdownAustralia: 359 citing papers, 2.9% of this breakdownFrance: 359 citing papers, 2.9% of this breakdownSpain: 346 citing papers, 2.8% of this breakdownJapan: 325 citing papers, 2.6% of this breakdownNetherlands: 264 citing papers, 2.2% of this breakdownSwitzerland: 232 citing papers, 1.9% of this breakdown
0%31.8%Other 21%

Fields

  • Medicine47.6%
  • Biochemistry, Genetics and Molecular Biology47.1%
  • Immunology and Microbiology1.5%
  • Engineering0.7%
  • Agricultural and Biological Sciences0.6%
  • Chemistry0.6%
  • Other1.9%

Topics

  • Prostate Cancer Treatment and Research10%
  • Cancer Genomics and Diagnostics5%
  • Prostate Cancer Diagnosis and Treatment4.2%
  • Epigenetics and DNA Methylation3.2%
  • Cancer-related molecular mechanisms research2.4%
  • PARP inhibition in cancer therapy2.3%
  • Other72.9%

Coauthors

All papers

Open in search
  1. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 3,701

  2. The mutational landscape of lethal castration-resistant prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2012 cited by 2,607

  3. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Liying Zhang, Ahmet Zehir, Joseph Vijai, Howard I. Scher, Charles L. Sawyers, Nikolaus Schultz, Philip W. Kantoff, David B. Solit, Mark E. Robson, Eliezer M. Van Allen, Kenneth Offit, Johann S. de Bono, Peter S. Nelson - New England Journal of Medicine 2016 cited by 1,663

  4. The long tail of oncogenic drivers in prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wassim Abida, Barry S. Taylor, Howard I. Scher, Peter S. Nelson, Johann S. de Bono, Mark A. Rubin, Charles L. Sawyers, Arul M. Chinnaiyan, Nikolaus Schultz, Eliezer M. Van Allen - Nature Genetics 2018 cited by 884

  5. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2009 cited by 2,262

  6. Integrative clinical genomics of metastatic cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Moshe Talpaz, Marcin Cieslik, Arul M. Chinnaiyan - Nature, Nat. 2017 cited by 938

  7. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Cell 2018 cited by 609

  8. Activating ESR1 mutations in hormone-resistant metastatic breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Genetics 2013 cited by 1,158

  9. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer

    Authors: , , , , , , , , , , , , , , , , - Nature 2019 cited by 298

  10. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Andrea Sboner, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 591

  11. Identification of Targetable FGFR Gene Fusions in Diverse Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2013 cited by 738

  12. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Genetics 2013 cited by 819

  13. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 cited by 159

  14. PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma

    Authors: , , , , , , , , , , - Cancer Research 2012 cited by 293

  15. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Valerie P. Castle, Raymond J. Hutchinson, Moshe Talpaz, Dan R. Robinson, Arul M. Chinnaiyan - JAMA 2015 cited by 416

  16. An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2010 cited by 857

  17. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment

    Authors: , , , , , , , , , , , - European Urology 2015 cited by 394

  18. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 210

  19. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Science 2008 cited by 1,056

  20. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2011 cited by 351

  21. The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing

    Authors: , , , , , , , , , , , , , - Genome Research 2015 cited by 191

  22. Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2011 cited by 421

  23. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist

    Authors: , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2009 cited by 172

  24. Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Research 2017 cited by 106